Amendments

1. (Cancelled).

2. (Cancelled).

3. (Currently Amended) ~~The~~ A therapeutic composition ~~of claim 2, wherein each tablet contains about~~ in tablet form for the symptomatic relief of cough and nasal decongestion associated with adverse respiratory tract conditions in warm-blooded animals in need of such treatment, said composition comprising pharmaceutically effective amounts of active ingredients, wherein said active ingredients consist of 20 to 30 mg of phenylephrine tannate, ~~about~~ 40 to 80 mg of pyrilamine tannate, and ~~about~~ 100 to 400 mg of guaifenesin.

4. (Currently Amended) The therapeutic composition of claim [[2]] 3, wherein said tablet form contains about 25 mg of phenylephrine tannate, about 60 mg of pyrilamine tannate, and about 200 mg of guaifenesin.

5. (Currently Amended) The therapeutic composition of claim [[2]] 3, wherein said tablet form contains about 25 mg of phenylephrine tannate, about 60 mg of pyrilamine tannate, and about 300 mg of guaifenesin.

6. (Cancelled).

7. (Currently Amended) ~~The~~ A therapeutic composition ~~of claim 6, wherein said suspension form contains about~~ in suspension form for the symptomatic relief of cough and nasal decongestion associated with adverse respiratory tract conditions in warm-blooded animals in need of such treatment, said composition comprising pharmaceutically effective amounts of active ingredients, wherein said active ingredients consist of 3 to 15 mg of phenylephrine tannate, ~~about~~ 25 to

35 mg of pyrilamine tannate, and ~~about~~ 50 to 300 mg of guaifenesin, per 5 ml of suspension.

8. (Currently Amended) The therapeutic composition of claim [[6]] 7, wherein said suspension form contains about 5 mg of phenylephrine tannate, about 30 mg of pyrilamine tannate, and about 100 mg of guaifenesin, per 5 ml of suspension.

9. (Currently Amended) The therapeutic composition of claim [[6]] 7, wherein said suspension form contains about 5 mg of phenylephrine tannate, about 30 mg of pyrilamine tannate, and about 200 mg of guaifenesin, per 5 ml of suspension.

10. (Withdrawn-currently amended). A method for symptomatically treating and relieving the distress of cough and nasal congestion associated with adverse respiratory tract conditions in warm-blooded animals, comprising orally administering to warm-blooded animals in need of such treatment the composition of claim [[1]] 3 or claim 7.

11. (Canceled).

12. (Withdrawn-currently amended). The method of claim [[11]] 10, wherein each tablet contains about 20 to 30 mg of phenylephrine tannate, about 40 to 80 mg of pyrilamine tannate, and about 100 to 400 mg of guaifenesin.

13. (Withdrawn-currently amended). The method of claim [[11]] 10, wherein said tablet form contains about 25 mg of phenylephrine tannate, about 60 mg of pyrilamine tannate, and about 200 mg of guaifenesin.

14. (Withdrawn-currently amended). The method of claim [[11]] 10, wherein said tablet form contains about 25 mg of phenylephrine tannate, about 60 mg of pyrilamine tannate, and about 300 mg of guaifenesin.

15. (Canceled).

16. (Withdrawn-currently amended). The method of claim [[15]] 10, wherein said suspension form contains about 3 to 15 mg of phenylephrine tannate, about 25 to 35 mg of pyrilamine tannate, and about 50 to 300 mg of guaifenesin, per 5 ml of suspension.

17. (Withdrawn-currently amended). The method of claim [[15]] 10, wherein said suspension contains about 5 mg of phenylephrine tannate, about 30 mg of pyrilamine tannate, and about 100 mg of guaifenesin, per 5 ml of suspension.

18. (Withdrawn-currently amended). The method of claim [[15]] 10, wherein said suspension contains about 5 mg of phenylephrine tannate, about 30 mg of pyrilamine tannate, and about 200 mg of guaifenesin, per 5 ml of suspension.

19. (Withdrawn). The method of claim 10, wherein said oral administration is a twice a day administration.

20. (New). A therapeutic composition in tablet form for the symptomatic relief of cough and nasal decongestion associated with adverse respiratory tract conditions in warm-blooded animals in need of such treatment, obtained by combining 20 to 30 mg of phenylephrine tannate, 40 to 80 mg of pyrilamine tannate, 100 to 400 mg of guaifenesin and one or more suitable pharmaceutical carriers, binding agents, and/or disintegrating agents.

21. (New). The therapeutic composition of claim 20, obtained by combining about 25 mg of phenylephrine tannate, about 60 mg of pyrilamine tannate, and about 200 mg of guaifenesin and one or more suitable pharmaceutical carriers, binding agents, and/or disintegrating agents.

22. (New). The therapeutic composition of claim 20, obtained by combining about 25 mg of phenylephrine tannate, about 60 mg of pyrilamine tannate, and about 300 mg of guaifenesin and one or more suitable pharmaceutical carriers, binding agents, and/or disintegrating agents.

23. (New). A therapeutic composition in suspension form for the symptomatic relief of cough and nasal decongestion associated with adverse respiratory tract conditions in warm-blooded animals in need of such treatment wherein said composition is obtained by combining 3 to 15 mg of phenylephrine tannate, 25 to 35 mg of pyrilamine tannate, 50 to 300 mg of guaifenesin with the proper amounts of pectin, kaolin, magnesium aluminum silicate, benzoic acid, methylparaben and glycerin per 5 ml of suspension.

24. (New). The therapeutic composition of claim 23, obtained by combining about 5 mg of phenylephrine tannate, about 30 mg of pyrilamine tannate, about 100 mg of guaifenesin and the appropriate amounts of pectin, kaolin, magnesium aluminum silicate, benzoic acid, methylparaben and glycerin to form a 5 ml suspension.

25. (New). The therapeutic composition of claim 23, obtained by combining about 5 mg of phenylephrine tannate, about 30 mg of pyrilamine tannate, about 200 mg of guaifenesin and the appropriate amounts of pectin, kaolin, magnesium aluminum silicate, benzoic acid, methylparaben and glycerin to form a 5 ml suspension.